地高辛停用与射血分数降低心力衰竭患者结局的关系
该研究基于OPTIMIZE-HF注册数据,纳入3499例既往服用地高辛的住院HFrEF患者,通过倾向评分匹配698对患者,比较停药与继续用药的结局。结果显示停药与4年心衰再住院、全因再住院及复合终点风险显著升高相关,全因死亡风险无显著差异;30天时停药与全因死亡风险升高相关。
要点
- 住院HFrEF患者停用地高辛与4年心衰再住院和全因再住院风险升高相关。
- 停药与30天全因死亡风险升高相关,但4年全因死亡风险无显著差异。
- 对于已服用地高辛的HFrEF患者,停药需谨慎评估。
核心结论
- 在接收现代指南指导药物治疗的住院老年HFrEF患者中,停用入院前地高辛治疗与不良结局相关。
研究设计与样本
- 基于Medicare链接的OPTIMIZE-HF注册研究,纳入11900例住院HFrEF(EF≤45%)患者,其中3499例入院前服用地高辛,721例停药。
- 采用倾向评分匹配形成698对患者,匹配50项基线特征:平均年龄76岁,平均EF 28%,女性41%,非裔美国人13%,使用β受体阻滞剂者65%。
主要发现
- 出院后4年,地高辛停药与心衰再住院风险显著升高相关(HR 1.21;95%CI 1.05-1.39;p=0.007)。
- 停药与全因再住院风险显著升高相关(HR 1.16;95%CI 1.04-1.31;p=0.010)。
- 停药与心衰再住院或全因死亡复合终点风险显著升高相关(HR 1.20;95%CI 1.07-1.34;p=0.002)。
- 停药与全因死亡风险无显著相关(HR 1.09;95%CI 0.97-1.24;p=0.163)。
- 出院后30天,停药与全因死亡风险升高相关(HR 1.80;95%CI 1.26-2.57;p=0.001),与复合终点风险升高相关(HR 1.36;95%CI 1.09-1.71;p=0.007)。
临床怎么用
- 对于已服用地高辛的住院HFrEF患者,停用地高辛前应权衡再住院和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The deleterious effects of discontinuation of digoxin on outcomes in ambulatory patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) receiving angiotensin-converting enzyme inhibitors are well-documented. OBJECTIVES: The authors sought to determine the relationship between digoxin discontinuation and outcomes in hospitalized patients with HFrEF receiving more contemporary guideline-directed medical therapies including beta-blockers and mineralocorticoid receptor antagonists. METHODS: Of the 11,900 hospitalized patients with HFrEF (EF ≤45%) in the Medicare-linked OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry, 3,499 received pre-admission digoxin, which was discontinued in 721 patients. Using propensity scores for digoxin discontinuation, estimated for each of the 3,499 patients, a matched cohort of 698 pairs of patients, balanced on 50 baseline characteristics (mean age 76 years; mean EF 28%; 41% women; 13% African American; 65% on beta-blockers) was assembled. RESULTS: Four-year post-discharge, digoxin discontinuation was associated with significantly higher risks of HF readmission (hazard ratio [HR]: 1.21; 95% confidence interval [CI]: 1.05 to 1.39; p = 0.007), all-cause readmission (HR: 1.16; 95% CI: 1.04 to 1.31; p = 0.010), and the combined endpoint of HF readmission or all-cause mortality (HR: 1.20; 95% CI: 1.07 to 1.34; p = 0.002), but not all-cause mortality (HR: 1.09; 95% CI: 0.97 to 1.24; p = 0.163). Discontinuation of digoxin was associated with a significantly higher risk of all 4 outcomes at 6 months and 1 year post-discharge. At 30 days, digoxin discontinuation was associated with higher risks of all-cause mortality (HR: 1.80; 95% CI: 1.26 to 2.57; p = 0.001) and the combined endpoint (HR: 1.36; 95% CI: 1.09 to 1.71; p = 0.007), but not of HF readmission (HR: 1.19; 95% CI: 0.90 to 1.59; p = 0.226) or all-cause readmission (HR: 1.03; 95% CI: 0.84 to 1.26; p = 0.778). CONCLUSIONS: Among hospitalized older patients with HFrEF on more contemporary guideline-directed medical therapies, discontinuation of pre-admission digoxin therapy was associated with poor outcomes.
引用
- Malik A, Masson R, Singh S, et al. Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019. PMID: 31370952. doi:10.1016/j.jacc.2019.05.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。